SCHEMBL13601680

SCHEMBL13601680

CCCCOC(=O)C(=O)N1CCC(C)CC1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.56
MAPT P10636 2/20 0.50
GAA P10253 1/20 0.48
NPC1 O15118 2/20 0.46
ALDH1A1 P00352 6/20 0.44
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
LMNA P02545 3/20 0.44
POLB P06746 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
LIPE Q05469 1/20 0.41
HRH3 Q9Y5N1 3/20 0.41
RAB9A P51151 1/20 0.39
ATM Q13315 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13601682 0.94 HPGD (0.50) HPGDMAPTGAANPC1ALDH1A1
SCHEMBL13601676 0.90 MAPT (0.53) HPGDMAPTGAANPC1ALDH1A1
SCHEMBL13601690 0.84 MAPT (0.44) HPGDMAPTGAANPC1ALDH1A1
SCHEMBL7339506 0.83 LMNA (0.61) HPGDMAPTGAANPC1ALDH1A1
SCHEMBL13601675 0.83 MAPT (0.70) HPGDMAPTGAANPC1ALDH1A1
SCHEMBL28060009 0.81 ALDH1A1 (0.53) HPGDMAPTNPC1ALDH1A1MEN1
SCHEMBL13601693 0.81 MAPT (0.46) HPGDMAPTGAANPC1ALDH1A1
SCHEMBL13601726 0.80 SMN1; SMN2 (0.45) HPGDMAPTGAANPC1ALDH1A1
SCHEMBL5875276 0.79 SMN1; SMN2 (0.44) HPGDMAPTGAAALDH1A1MEN1
SCHEMBL12881455 0.78 GNAI3 (0.58) MAPTGAASMN1; SMN2L3MBTL1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7625886-B2 Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-12-01 US disclosed
US-7625886-B2 Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-12-01 US disclosed